ES2839211T3 - Método para purificar proteínas de fusión a albúmina - Google Patents
Método para purificar proteínas de fusión a albúmina Download PDFInfo
- Publication number
- ES2839211T3 ES2839211T3 ES16762595T ES16762595T ES2839211T3 ES 2839211 T3 ES2839211 T3 ES 2839211T3 ES 16762595 T ES16762595 T ES 16762595T ES 16762595 T ES16762595 T ES 16762595T ES 2839211 T3 ES2839211 T3 ES 2839211T3
- Authority
- ES
- Spain
- Prior art keywords
- sequence
- comprises seq
- loop
- seq
- loop comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132198P | 2015-03-12 | 2015-03-12 | |
| PCT/US2016/022003 WO2016145307A1 (en) | 2015-03-12 | 2016-03-11 | Method of purifying albumin-fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2839211T3 true ES2839211T3 (es) | 2021-07-05 |
Family
ID=56878920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16762595T Active ES2839211T3 (es) | 2015-03-12 | 2016-03-11 | Método para purificar proteínas de fusión a albúmina |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10683340B2 (enExample) |
| EP (2) | EP3268389B1 (enExample) |
| JP (4) | JP6862348B2 (enExample) |
| KR (2) | KR20170124592A (enExample) |
| CN (1) | CN107428817B (enExample) |
| AU (4) | AU2016228806B2 (enExample) |
| CA (2) | CA3260163A1 (enExample) |
| ES (1) | ES2839211T3 (enExample) |
| IL (1) | IL253971B (enExample) |
| WO (1) | WO2016145307A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102434073B1 (ko) | 2011-10-11 | 2022-08-18 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| EP3793612A4 (en) | 2018-05-16 | 2022-03-02 | LIB Therapeutics, LLC | COMPOSITIONS CONTAINING PCSK9 BINDING MOLECULES AND METHODS OF USE |
| BR112021008797A2 (pt) * | 2018-11-09 | 2021-08-31 | Neopep Pharma Gmbh & Co. Kg | Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame |
| EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| CN110295152A (zh) * | 2019-07-29 | 2019-10-01 | 北京泓恩生物科技有限公司 | 一种重组产朊假丝酵母尿酸酶的纯化方法 |
| IL309560B2 (en) * | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| WO2021203013A2 (en) | 2020-04-03 | 2021-10-07 | Viela Bio, Inc. | Methods of treating immune mediated pulmonary injury |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| EP4175969A4 (en) * | 2020-07-01 | 2024-07-24 | Medimmune, LLC | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPY AGENT |
| CN112062833A (zh) * | 2020-10-09 | 2020-12-11 | 国药集团武汉血液制品有限公司 | 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法 |
| CN115677848A (zh) * | 2022-10-24 | 2023-02-03 | 通化安睿特生物制药股份有限公司 | 一种制备高纯度高稳定性蛋白质的方法 |
| CN120712138A (zh) * | 2022-10-25 | 2025-09-26 | 唐纳森公司 | 含有碳水化合物结合结构域的分子的分离介质和纯化方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| CA2079802C (en) | 1990-04-05 | 2001-09-18 | Roberto Crea | Walk-through mutagenesis |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| CA2350417C (en) | 1998-12-02 | 2010-02-09 | Bristol-Myers Squibb Company | Dna-protein fusions and uses thereof |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2377468C (en) | 1999-07-27 | 2010-04-20 | Phylos, Inc. | Peptide acceptor ligation methods |
| US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| WO2003000856A2 (en) | 2001-06-21 | 2003-01-03 | Phylos, Inc. | In vitro protein interaction detection systems |
| KR100524872B1 (ko) * | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| ATE528396T1 (de) | 2004-07-06 | 2011-10-15 | Bioren Inc | Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften |
| AU2006329215A1 (en) | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Process for the production of preformed conjugates of albumin and a therapeutic agent |
| JP5518702B2 (ja) | 2007-07-03 | 2014-06-11 | ダヌタ・クルセフスカ | α−ケトグルタレートの新規の医学的用途 |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2215246B1 (en) | 2007-10-31 | 2015-01-07 | MedImmune, LLC | Protein scaffolds |
| MX2011004550A (es) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos. |
| CN102596992B (zh) | 2009-02-12 | 2015-09-09 | 詹森生物科技公司 | 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途 |
| CN102549012B (zh) * | 2009-05-07 | 2015-07-01 | 诺维信生物制药丹麦公司 | 纯化白蛋白的方法 |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
| KR20130056870A (ko) | 2010-04-13 | 2013-05-30 | 메디뮨 엘엘씨 | 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드 |
| EP2675471A4 (en) | 2011-02-15 | 2015-01-28 | Medimmune Llc | HSA-RELATED COMPOSITIONS AND USE PROCESSES |
| KR102434073B1 (ko) * | 2011-10-11 | 2022-08-18 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| CA2890766A1 (en) * | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
-
2016
- 2016-03-11 JP JP2017548053A patent/JP6862348B2/ja active Active
- 2016-03-11 WO PCT/US2016/022003 patent/WO2016145307A1/en not_active Ceased
- 2016-03-11 CN CN201680014597.2A patent/CN107428817B/zh active Active
- 2016-03-11 AU AU2016228806A patent/AU2016228806B2/en active Active
- 2016-03-11 EP EP16762595.3A patent/EP3268389B1/en active Active
- 2016-03-11 US US15/557,358 patent/US10683340B2/en active Active
- 2016-03-11 CA CA3260163A patent/CA3260163A1/en active Pending
- 2016-03-11 KR KR1020177028780A patent/KR20170124592A/ko not_active Ceased
- 2016-03-11 ES ES16762595T patent/ES2839211T3/es active Active
- 2016-03-11 CA CA2977675A patent/CA2977675A1/en active Pending
- 2016-03-11 EP EP20198757.5A patent/EP3842451A1/en active Pending
- 2016-03-11 KR KR1020247016329A patent/KR20240093725A/ko active Pending
-
2017
- 2017-08-14 IL IL253971A patent/IL253971B/en unknown
-
2020
- 2020-06-15 US US16/901,812 patent/US11548933B2/en active Active
-
2021
- 2021-01-22 AU AU2021200423A patent/AU2021200423B2/en active Active
- 2021-03-31 JP JP2021061713A patent/JP7320550B2/ja active Active
-
2023
- 2023-01-06 US US18/150,983 patent/US20230340074A1/en active Pending
- 2023-05-16 JP JP2023080507A patent/JP7826243B2/ja active Active
- 2023-07-03 AU AU2023204271A patent/AU2023204271B2/en active Active
-
2026
- 2026-02-25 JP JP2026027948A patent/JP2026094244A/ja active Pending
- 2026-03-13 AU AU2026201911A patent/AU2026201911A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023204271B2 (en) | Method of purifying albumin-fusion proteins | |
| CA3059994C (en) | Human coagulation factor ix (fix) fusion protein, preparation method therefor, and use thereof | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| KR20210149779A (ko) | Fc 영역 개변 항체의 정제 방법 | |
| JP6352354B2 (ja) | 非ペプチドヒンジ部含有フレキシブル抗体様分子 | |
| JP2024539653A (ja) | 生体液を精製するための組成物及び方法 | |
| CN112969477B (zh) | 改善肽的血液动力学的方法 | |
| KR20250148832A (ko) | 알부민 융합 단백질의 정제방법 | |
| HK1245286B (en) | Method of purifying albumin-fusion proteins | |
| BR112017019401B1 (pt) | Método de purificação de proteínas de fusão de albumina | |
| RU2820588C2 (ru) | Способы очистки гетеродимерных полиспецифических антител | |
| WO2023133594A2 (en) | Stabilized single immunoglobulin variable domains | |
| HK40090436A (en) | Cd40l-specific tn3-derived scaffolds and methods of use thereof | |
| HK40027581B (en) | Method of purifying glycosylated protein from host cell galectins and other contaminants |